ASH: Adding Subcutaneous Daratumumab Slows Advanced Multiple Myeloma
TUESDAY, Dec. 8, 2020 — For patients with relapsed/refractory multiple myeloma (RRMM), subcutaneous daratumumab plus pomalidomide and dexamethasone (D-Pd) reduces
Read more
TUESDAY, Dec. 8, 2020 — For patients with relapsed/refractory multiple myeloma (RRMM), subcutaneous daratumumab plus pomalidomide and dexamethasone (D-Pd) reduces
Read moreHollings Cancer Center researchers at the Medical University of South Carolina (MUSC) and colleagues assessed the connection between dietary advanced
Read moreAn international study demonstrates that administering niraparib after conventional chemotherapy treatment in patients newly diagnosed with advanced ovarian cancer, improves
Read moreEarly palliative care is associated with better survival in patients with advanced lung cancer, according to a study by VA
Read moreBeing able to identify targets for adoptive cell therapies is one of the first steps in developing personalized treatments for
Read moreIn a new study including Yale Cancer Center and Smilow Cancer Hospital researchers, the cancer immunotherapy drug pembrolizumab (Keytruda), increased
Read moreLocally advanced pancreatic cancer (LAPC) – a tumor that, while still confined to the pancreas, involves major abdominal blood vessels—is
Read moreAn Ontario clinical study that shows adding PET imaging to conventional CT imaging to stage locally advanced cervix cancer can
Read moreWEDNESDAY, Aug. 15, 2018 — Single-agent talazoparib provides significant benefit over standard chemotherapy for patients with advanced breast cancer and
Read moreFRIDAY, July 6, 2018 — Cabozantinib results in significantly longer overall and progression-free survival than placebo among patients with advanced
Read more